This can occur in disorders of the carnitine cycle (carnitine-acylcarnitine translocase [CACT] or carnitine palmitoyl transferase 2 [CPT-2] deficiency) and fatty acid oxidation (MCAD, VLCAD, LCHAD, TFP deficiency), organic acidemias (propionic, methylmalonic, isovaleric, and glutaric acidemia, 3-methylcrotonylglycinuria, multiple carboxylase deficiency, and other more rare), renal disease (renal Fanconi syndrome, chronic renal failure, dialysis), lysinuric protein intolerance (LPI), chronic ketosis or ketogenic diet, extreme prematurity, prolonged use of intravenous nutrition not supplemented by carnitine, and drug therapy (valproic acid, phenobarbital, phenytoin, carbamazepine, drugs containing pivalic acid)
It may also regulate melanin production by the release of the -melanocyte stimulating hormone and the precipitation of zinc-2-glycoprotein in tissues
CL Protein Assay: A reducing agent Compatible Lowry Protein Assay that is compatible with common laboratory agents known to interfere with Lowry protein assays, including reducing agents (dithiothreitol (DTT), -mercaptoethanol and TCEP), detergents, chelating agents, amines, sugars, strong chaotropic buffers, salts, drugs, antibiotics, cobalt and other common laboratory agents
